Finding Affordable Ketamine Treatment: Options and Strategies

Finding affordable ketamine treatment starts with matching the delivery method to your insurance status and budget, not chasing the lowest sticker price alone. Ketamine therapy uses low, controlled doses of the anesthetic ketamine, delivered as an IV infusion, an intramuscular (IM) injection, an intranasal esketamine spray sold under the brand name Spravato, or an at-home sublingual tablet program, to treat conditions such as treatment-resistant depression and chronic pain. Treatment-resistant depression is major depressive disorder that has not improved after at least two adequate trials of standard antidepressant medication.

Most forms of ketamine therapy are not routinely covered by insurance, and out-of-pocket costs can range from a few hundred dollars a month to tens of thousands of dollars a year. That gap keeps many patients from starting or continuing treatment that could help them. This guide breaks down real cost ranges across delivery methods, explains which path is most likely to get insurance coverage, and walks through payment plans, HSA and FSA rules, clinical trials, and other ways to lower the cost of ketamine therapy without giving up on treatment.

Before choosing a cost-saving strategy, it helps to see what each delivery method actually costs and how often insurance applies. The table below compares the four main forms of ketamine therapy.

Spravato is the only ketamine-based option currently reviewed and approved by the FDA specifically for treatment-resistant depression, which is why it has the clearest path to insurance coverage. According to the FDA, esketamine nasal spray was approved in 2019 for use alongside an oral antidepressant in adults with treatment-resistant depression, administered under direct medical supervision. Because it carries this approval, many commercial insurance plans and Medicare Part B cover Spravato when a patient meets diagnostic criteria, though prior authorization and documentation of prior failed antidepressant trials are usually required.

IV ketamine, IM ketamine, and at-home sublingual programs are generally used off-label for depression, anxiety, PTSD, and chronic pain. Off-label means a drug is being used for a condition or in a form the FDA has not specifically approved for that use, even when the practice is common and supported by clinical research. Insurers rarely reimburse off-label ketamine treatment, which is why these options are typically priced as self-pay. See our ketamine vs. esketamine comparison for more on how these forms differ in mechanism, delivery, and clinical use.

Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can offset ketamine treatment costs even when insurance does not cover the treatment itself. Both account types let you pay for qualified medical expenses with pretax dollars, and the IRS treats medically necessary treatment prescribed by a licensed provider as an eligible expense under Publication 969. Ask your clinic for an itemized receipt, sometimes called a superbill, listing the billing codes, diagnosis, and provider information, since HSA and FSA administrators generally require this documentation before approving reimbursement.

Beyond HSA and FSA funds, a few other strategies can lower the real cost of treatment:

Payment plans. Many ketamine clinics offer in-house financing or work with third-party medical lenders to spread the cost of an initial IV or IM series over several months.

Package pricing. Clinics often discount a bundled series of IV or IM sessions compared with paying per visit, since an initial course is usually needed before response can be assessed.

Maintenance step-down. Patients who respond to an initial IV, IM, or Spravato series can often move to lower-frequency booster sessions or an at-home sublingual maintenance plan, which reduces ongoing cost once acute treatment is complete. Our maintenance treatment guide covers how that transition typically works, and our oral vs. sublingual ketamine guide explains how at-home dosing differs from in-clinic delivery.

Clinical trials. Actively enrolling ketamine and esketamine research studies, listed on ClinicalTrials.gov, sometimes provide treatment at no cost to eligible participants in exchange for research data. Eligibility criteria and site availability vary, and not every region has an open trial.

Sliding-scale and nonprofit programs. Some university-affiliated psychiatry programs and nonprofit mental health clinics offer income-based sliding-scale fees for ketamine or esketamine treatment, though availability depends on location and program capacity.